Testagen 20mg we yu de yuz

▎ Tɛstagen Strukchɔ

▎ Testagen Risach

Wetin na di risach bakgrɔn fɔ Testagen?

Agens di bakdrop fכ advans mכdan bayoteknכlכji εn bayomεdikal risεch, di εksplכreshכn fכ bayoaktiv pεptida dεm dכn bi wan siknifikant risεch dairekshכn na di fil. as sεntetik pεptida, Testagen hכld notabl risεch sכmtin biכs fכ in pכtεnshal valyu in sεlyul prכsεs, tisu rigεnεreshכn, mεtabolik path dεm, εn כda fisiolכjik εn bayokεmik sistεm dεm. we i de pan di kategori fכ bayoaktiv pεpti dεm, di Testagen de kכmכp

 di amino asid sikεns dεm we kin infכlכw di sεl-mכlikul intarakshכn dεm. in strכkchכ dεn dεn mek am fכ miks כ sכpכt εndojεnik bayolojikal prכsεs dεm, so dat i de prεzεnt pכtεnshal as risεch sכbjεkt insay mכlikul bayoloji, bayokεmistri, εn rigεnεraytiv risεch.

Figure 1. Bayorεgulεshכn sistεm fכ wan mכlti sεlyul כganism. 

Sos: MDPI ^{[1] we dɛn pul am.}

Wetin na di we aw Tɛstajɛn de du sɔntin?

Sεl Pεnεtreshכn: stכdi dεn sho se afta dεn inkכba HeLa sεl dεm wit fluorescein isothiocyanate-labeled Testagen, dεn si difrεnt fכrosεns insay di saytoplasm, sεl nyuklios, εn nyuklios, we sho se Testagen gεt di abiliti fכ pεnεtrate animal sεl dεm εn dεn nyuklios. in kapasiti fכ travεs sεl mεmbran dεm εn nyuklia mεmbran dεm insay di sεl intyriכ kin riliyt to sכm transpכt protin dεm na di sεl mεmbran כ mεmbran fכ fכm. di sεl mεmbran nכto wan strכkchכ we nכ de pas fכ kכmplit; i gεt chanεl dεm εn transpכt mεkanism dεm. testagen kin enta sεl dεm bay we i de intarakt wit dεn transpכt protin dεm ya כ tru εndosaytosis lεk mεkanism dεm we de yuz mεmbran fכluiditi, we de lay di fכndashכn fכ in sכbsכktiv ifekt dεm ^{[2] .}.  

spεsifi k intarakshכn wit Nyukliyk Asid dεm: difrεn intakt pεptida dεm we kכmכt de sho difrεn ifekt dεm pan di fכrosεns fכ 5,6-kabכksifluoresεn-lεbul dεoxyoligonucleotides εn DNA-ethidium bromide kכmpleks dεm. bay we dεn mεzj Stern-Volmer kכnstant dεm, dεn fכnshכn se Testagen, we dεn kכmpεr wit כda sכt pεptida dεm, de indyuz difrεn digri dεm fכ fכrosεns kεnch insay singl-strand εn dכbl-strand fכrosεnt lεbul dεoxyoligonucleotides, dipכnt pan di pεptida in praymar strכkchכ. dis de sho spεsifi k intarakshכn bitwin Testagen εn nyukliyk asid strכkchכ dεm. we i de biεn nyukliyk asid, Testagen kin difrεnt bitwin difrεn nyukliotayd sikεns dεm εn ivin no dεn saytosin mεtyleshכn stetכs. fכ egzampl, i tan lεk se Testagen de fכs fכ biεn to dioxyoligonucleotides we gεt CAG sikεns dεm. dis kayn spεsifi k binding kin bi tru nכn-kכvalεnt intarakshכn lεk haydrojεn bכnd εn ilektrostatik intarakshכn bitwin amino asid rεsidεns dεm na di Tεstajεn mכlikul εn di bays כ fכsfεt bakbכn dεm fכ nyukliyk asid dεm. dis spεsifisiti de alaw Testagen fכ prεsis lokaliz to spεsifi k nyukliyk asid rijyכn dεm, we de infכlכw prכsεs dεm lεk jin εksprεshכn ^{[2] .}.  

di epijenεtik rεguleshכn fכ di sεlyul jεnεtik fכnshכn dεm: bikoz fכ in abiliti fכ spεshal biεn to DNA, di sayt-spεsifi k intarakshכn dεm we Testagen de du wit DNA kin kכntro di sεlyul jεnεtik fכnshכn dεm na di epijεnik lεvεl. epijεnik rεguleshכn nכ de altεr di DNA bays sikεns bכt i de infכlכw jin εksprεshכn tru DNA modifyushכn (εgz., mεtyleshכn) εn histכn modifyushכn. tεstajen kin biεn spεsifi k DNA rijyכn dεm, we de afekt kromatin strכkchכ na dεn rijyכn dεm de כ rikrut epijεnεtik rεgεdyushכn protin fכktכ dεm fכ mכdulet jin transkripshכnal aktiviti. dis kayn rεgulεshכn fכ di jin aktiviti kin dכn ple imכtant rol insay di fכs stej dεm fכ layf in כrijin εn bayolojikal εvolushכn, we de εp כganism dεm fכ rεgεl jin εksprεshכn prεsishכn insay difrεn envayroment dεm fכ adap to chenj dεm εn komplit layf prכsεs dεm ^{[2] .}.  

Efεkt pan εndokrin Fכnshכn pan Krכnik Nכn-Bakterial Prכstataytis Pasεnt dεm: Insay mεdikal risach, stכdi dεm pan pasεnshכn wit krεse nכn-bakterial prכstataytis (IIIA) dεn fכnshכn se afta wan mכnt kכnsyuv tritmεnt wit wan rεjim we inklud Testagen (α1-adrenergic blockers + rεktal suppositories we kכntεn nכn-stεroyd anti-inflammatory drugs), urodynamic paramita dεm signifyant improv, di prostat inflameshn lεvεl dεm dכn dכn, εn di sεrum tכtal tεstostεron lεvεl dεm dכn inkrεs. dis sho se Testagen kin rεgεl εndokrin bεlε tru sכm mεkanism dεm. wan plausibul mεkanism na dat Testagen de infכlכw signal path dεm we riliyt to tεstostεron sεntez insay Leydig sεl dεm. tεstostεron sεntesis na kכmpleks prכsεs we involv mכltipכl εnzym dεm εn signal mכlikul dεm. di tεstajen kin aktibכt כ inhεbit di rilayt signal path dεm bay we i de biεn to di intasεlulyar rεsεpכta dεm, we de mek di tεstostεron sεntez, impruv di sikman in εndokrin stetכs, εn i de mek di simptom dεm fכ krεse nכn-bakterial prכstataytis ^[3]..  

Wetin na di aplikeshɔn dɛn fɔ Testagen?  

Tritmɛnt fɔ Kronik Nɔn-bakterial Prɔstataytis: Kronik nɔ-bakterial prɔstataytis (IIIA), we kin kam wit di lɔwa urinary tract simptom dɛm, kin ambɔg di sikman dɛn kwaliti fɔ layf bad bad wan. Testagen de ple imכtant rol fכ trit dεn kayn kכndyushכn dεm ya ^[4] (Niu D, 2023). stכdi dεm we yuz wan kכnsyuv tritmεnt rεjim we kכmbayn α1-adrenergic blכk dεm, rεktal suppositories wit nכn-stεroyd anti-inflammatory drog dεm, εn Testagen achy remarkabl risכlt afta wan mכnt. di urodaynamik paramita dεm improv sכmtεm, we sho se di micturition fכnshכn εnhans εn rilif fכ di lכw urinary tract obstruction simptom dεm. pan tap dat, di intraprostatic inflameshn lεvεl dεm dכn dכn, we de rεdכks di tisu dεm we dεn dכn pwεl. di mכr imכtant, di sεrum tכtal tεstostεron lεvεl dεm inkrεs. tεstostεron implεnt fכ mεnten di nכmal fכnshכn fכ di man riprodaktiv sistεm, sεks fכnshכn, εn כvala mεtabolism, εn in εlevεshכn de εp fכ impruv di εndokrin dizכrd dεm we di sik de kכz ^[3]..  

Sεl Pεnεtreshכn εn Nyukliyk Asid Intarakshכn: As sכt bayoaktiv pεptida, Testagen de sho yunik sεlyul prכpati dεm we de fכm di bεsis fכ in mεdikal aplikεshכn dεm ^[2] (Fedoreyeva LI, 2011). insay HeLa sel εkspεriεns, dεn si signifyant fכrosεns insay di saytoplasm, nyuklios, εn nyuklios afta dεn inkכbeshכn wit fluorescein isothiocyanate-labeled Testagen, we sho se i ebul fכ pεnεtrate animal sεl dεm εn nyuklios. dis de alaw Testagen fכ enta sεl dεm εn intarakt wit intasεlulyar kכmכpכnεnt dεm, we de mek rεgεdyushכn fכnshכn dεm insay sεl dεm.  

stכdi dεn dכn fכnshכn se difrεn sכt bayoaktiv pεptida dεm de εksyεrt difrεn ifekt dεm pan di fכrosεns fכ 5,6-kכbכksifluoresεn-lεbul dεoxyribooligonucleotides εn DNA-ethidium bromide kכmpleks dεm. di fכrosεns kεnch lεvεl dεm, we dεn kכl Stern-Volmer kכnstant dεm, de difrεn bitwin sכt pεptida dεm lεk Testagen dipכnt pan dεn praymar strכkchכ we dεn de intarakt wit singl-strand εn dכbl-strand fכrosεnt lεbul dεoxyribooligonucleotides, we de sho spεsifi k intarakshכn wit nyukliyk asid strכkchכ dεm. fכda risεch sho se Testagen fכs fכ biεn to dioxyribooligonucleotides we gεt CAG sikεns dεm. dis abiliti fכ biεn spεsifi k nyukliyk asid sikεns dεm de sho se Testagen kin rεgεl sεlyul jεnεtik fכnshכn dεm na di epijεnik lεvεl tru sayt-spεsifi k DNA intarakshכn, we de ple wan kכl rol insay jin aktiviti rεgulεshכn. dis de hol pכtεnshal fכ divεlכp jin rεguleshכn-bεys tεrapi dεm—fכ egzampl, insay sik dεm we de asai wit abnכmal jin εksprεshכn. pan ɔl we dɛn nɔ dɔn ripɔt dairekt klinik aplikeshɔn dɛn yet, mɛkanikal stɔdi dɛn na di sɛlular ɛn mɔlikul lɛvɛl dɛn de pɔynt to fiuja mɛdikal aplikeshɔn dɛn.  

Dɔn  

fכ sכmari, Testagen dכn sho se i de trit krεse nכn-bakterial prכstataytis, we in prכpati dεm fכ sεl pεnεtreshכn εn nyukliyk asid intarakshכn de gi pכtεnshal fכ brayt mεdikal aplikεshכn. Wit mɔ risach, dɛn de op se i go ple impɔtant pat fɔ trit mɔ sik ɛn mɛrɛsin intavɛnshɔn.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Niu, Dun na bigman we sabi bɔt mɛrɛsin ɛn layf sayɛns. Afiliet wit prestij institiushɔn dɛm lɛk Ami Mɛdikal Yunivasiti ɛn Yunivasiti ɔf Sawt , i de pe atɛnshɔn pan in risach pan Famakɔlɔji & Famasi, Sɛl Bayoloji, Imyunɔlɔji, ɛn Bayokɛmistri & Mɔlikul Bayoloji. Dɛn disiplin ya rili impɔtant fɔ mek dɛn no aw di sik kin kam, fɔ mek nyu mɛrɛsin go bifo, ɛn fɔ mek mɔtalman gɛt wɛlbɔdi. Apat frɔm dat, Niu, Dun de du risach na di Cardiovascular System & Cardiology, we de ɛksplɔrɔ di pathogenesis ɛn tritmɛnt fɔ di sik dɛm we de kam pan di at. In wok de gi signifyant tiori fawndeshɔn ɛn prɛktikal gayd fɔ di klinik diagnosis ɛn tritmɛnt fɔ kadiovaskular sik dɛm, we de sho in dip ɛkspɛriɛns ɛn brayt inflɔɛns pan mɛdikal risach.. Niu, Dun is listed in the reference of citation [4].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Khavinson V. K., Popovich I. G. E., Linkova N. S., ɛn ɔda pipul dɛn. Pεptid Rεgulεshכn fכ Jin εksprεshכn: Wan Sεstεmatik Rivyu[J]. Mɔlikul dɛn, 2021,26(22},https://www.mdpi.com/1420-3049/26/22/7053

ATIKUL-NƆMBA = {7053).DOI:10.3390/mɔlikul dɛn26227053.

[2] Fedoreyeva L. I., Kireev II, Khavinson V, ɛn ɔda pipul dɛn. pεnεtreshכn fכ sכt fכrosεns-lεbul pεpti dεm insay di nyuklios insay HeLa sεl dεm εn in vitro spεsifi k intarakshכn fכ di pεptida dεm wit dioxy ribooligonucleotides εn DNA[J]. Bayokemistri-Mɔsko, 2011,76(11):1210-1219.DOI:10.1134/S0006297911110022.

[3] Rossikhin V, Hoshchenko Y, Osipov P. Efikכs כf tεstostεron sεntez induktכr aplikεshכn 'testagen' in andrכjεnik dεfisiεns in pasεnshכn wit krכnik abakterial prכstataytis[J]. Prɔblɛm dɛn fɔ Ɛndokrin Patɔlɔji, 2011,36:17-22.DOI:10.21856/j-PEP.2011.2.03.

[4] Niu D, Wu Y, Lian J. Sεkyulכr RNA vaksin in sik prεvεnshכn εn tritmεnt[J]. Signal Transdukshɔn ɛn Target Tɛrapi, 2023,8. https://api.semanticscholar.org/CorpusID:261662530, di wan dɛn we de stɔdi bɔt di Baybul.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto famasitik, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.